Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data
Covered in this story
What has happened since
- Vir Biotechnology Inc is up 12.4% since this was published, 7 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Raymond James’s $19 target on $VIR is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
Raymond James’s track record →Tracked from this story
H.C. Wainwright’s $20 target on $VIR is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
H.C. Wainwright’s track record →Call it yourself
No member calls on $VIR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Vir Biotechnology Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.